• MedSci Healthcare posted profit attributable to owners of RMB 10.64 million, down 19.7%, with EPS at RMB 1.94 cents.
• Revenue fell 6.2% to RMB 117.45 million; gross profit dropped 20.8% to RMB 61.33 million as cost of sales rose 17.5%.
• Physician platform solutions slid 30.1% to RMB 32.73 million, while precision omni-channel marketing rose 3.4% to RMB 58.05 million.
• Real-world clinical study solutions climbed 22.6% to RMB 20.39 million; data and artificial intelligence solutions increased 11.2% to RMB 6.28 million.
• DeepEvidence user base and token consumption rose about 250% year-on-year, with cumulative token consumption nearing the trillion-level mark.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedSci Healthcare Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12309988), on August 31, 2026, and is solely responsible for the information contained therein.